Literature DB >> 21908653

Incidence of hyperthyroidism in Sweden.

Mirna Abraham-Nordling1, Kristina Byström, Ove Törring, Mikael Lantz, Gertrud Berg, Jan Calissendorff, Helena Filipsson Nyström, Svante Jansson, Gun Jörneskog, F Anders Karlsson, Ernst Nyström, Hans Ohrling, Thomas Orn, Bengt Hallengren, Göran Wallin.   

Abstract

INTRODUCTION: The incidence of hyperthyroidism has been reported in various countries to be 23-93/100,000 inhabitants per year. This extended study has evaluated the incidence for ~40% of the Swedish population of 9 million inhabitants. Sweden is considered to be iodine sufficient country.
METHODS: All patients including children, who were newly diagnosed with overt hyperthyroidism in the years 2003-2005, were prospectively registered in a multicenter study. The inclusion criteria are as follows: clinical symptoms and/or signs of hyperthyroidism with plasma TSH concentration below 0.2 mIE/l and increased plasma levels of free/total triiodothyronine and/or free/total thyroxine. Patients with relapse of hyperthyroidism or thyroiditis were not included. The diagnosis of Graves' disease (GD), toxic multinodular goiter (TMNG) and solitary toxic adenoma (STA), smoking, initial treatment, occurrence of thyroid-associated eye symptoms/signs, and demographic data were registered.
RESULTS: A total of 2916 patients were diagnosed with de novo hyperthyroidism showing the total incidence of 27.6/100,000 inhabitants per year. The incidence of GD was 21.0/100,000 and toxic nodular goiter (TNG=STA+TMNG) occurred in 692 patients, corresponding to an annual incidence of 6.5/100,000. The incidence was higher in women compared with men (4.2:1). Seventy-five percent of the patients were diagnosed with GD, in whom thyroid-associated eye symptoms/signs occurred during diagnosis in every fifth patient. Geographical differences were observed.
CONCLUSION: The incidence of hyperthyroidism in Sweden is in a lower range compared with international reports. Seventy-five percent of patients with hyperthyroidism had GD and 20% of them had thyroid-associated eye symptoms/signs during diagnosis. The observed geographical differences require further studies.

Entities:  

Mesh:

Year:  2011        PMID: 21908653     DOI: 10.1530/EJE-11-0548

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  49 in total

Review 1.  The incidence and prevalence of thyroid autoimmunity.

Authors:  Donald S A McLeod; David S Cooper
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

2.  A Prospective Investigation of Graves' Disease and Selenium: Thyroid Hormones, Auto-Antibodies and Self-Rated Symptoms.

Authors:  Jan Calissendorff; Emil Mikulski; Erik H Larsen; Marika Möller
Journal:  Eur Thyroid J       Date:  2015-05-27

Review 3.  Role of genetic and non-genetic factors in the etiology of Graves' disease.

Authors:  M Marinò; F Latrofa; F Menconi; L Chiovato; P Vitti
Journal:  J Endocrinol Invest       Date:  2014-11-25       Impact factor: 4.256

4.  CD40 Signaling in Graves Disease Is Mediated Through Canonical and Noncanonical Thyroidal Nuclear Factor κB Activation.

Authors:  Hanna J Lee; Angela Lombardi; Mihaela Stefan; Cheuk Wun Li; William B Inabnet; Randall P Owen; Erlinda Concepcion; Yaron Tomer
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

Review 5.  The thyroid, the eyes and the gut: a possible connection.

Authors:  D Covelli; M Ludgate
Journal:  J Endocrinol Invest       Date:  2017-01-07       Impact factor: 4.256

6.  Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg.

Authors:  Letterio Salvatore Politi; Claudia Godi; Gabriella Cammarata; Alessandro Ambrosi; Antonella Iadanza; Roberto Lanzi; Andrea Falini; Stefania Bianchi Marzoli
Journal:  Eur Radiol       Date:  2014-02-12       Impact factor: 5.315

7.  Patient knowledge of antithyroid drug-induced agranulocytosis.

Authors:  Jonah Robinson; Max Richardson; Janis Hickey; Andy James; Simon H Pearce; Steve G Ball; Richard Quinton; Margaret Morris; Margaret Miller; Petros Perros
Journal:  Eur Thyroid J       Date:  2014-10-15

8.  Short-term effects of combined treatment with potassium bromide and methimazole in patients with Graves' disease.

Authors:  D Li; H Pei; X Li; X Liu; X Li; Y Xie
Journal:  J Endocrinol Invest       Date:  2011-12-16       Impact factor: 4.256

Review 9.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

10.  Description and evaluation of the first national patient and public involvement day for thyroid eye disease in the United Kingdom.

Authors:  Henry B Smith; Carol Porteous; Catey Bunce; Karen Bonstein; Janis Hickey; Colin M Dayan; Gill Adams; Geoff E Rose; Daniel G Ezra
Journal:  Thyroid       Date:  2014-07-21       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.